TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

NCT05384756 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Alemtuzumab
PROCEDURE: Hematopoietic Cell Transplantation
RADIATION: Intensity-Modulated Radiation Therapy
DRUG: Sirolimus

Sponsor

City of Hope Medical Center

Collaborators

[object Object]